Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis

JAMA Neurology

Volumn 73, Issue 11, 2016, Pages 1342-1348

  Damato, Valentina ^a   Evoli, Amelia ^a   Iorio, Raffaele ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB; TOCILIZUMAB; IMMUNOLOGIC FACTOR;

ADOLESCENT; ADULT; AGED; CHILD; CLINICAL TRIAL (TOPIC); DEATH; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE SCORE; FEMALE; HUMAN; INFECTION; INFUSION RELATED REACTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MYELOOPTIC NEUROPATHY; NEUROMYELITIS OPTICA SPECTRUM DISORDER; OUTCOME ASSESSMENT; PATIENT INFORMATION; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RATING SCALE; RELAPSE; REVIEW; SCHOOL CHILD; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT RESPONSE; MIDDLE AGED; NEUROMYELITIS OPTICA; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; OUTCOME ASSESSMENT (HEALTH CARE); RITUXIMAB; YOUNG ADULT;

EID: 84996837041     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2016.1637     Document Type: Review

References (64)

1. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106-2112.
2. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473-477.
3. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ,Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9): 805-815.
4. Iorio R, Pittock SJ. Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies. Clin Exp Neuroimmunol. 2014;5 (2):175-187. doi:10.1111/cen3.12103
5. Hinson SR, Romero MF, Popescu BF, et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A. 2012;109(4):1245-1250.
6. Iorio R, Fryer JP, Hinson SR, et al. Astrocytic autoantibody of neuromyelitis optica (NMO-IgG) binds to aquaporin-4 extracellular loops, monomers, tetramers and high order arrays. J Autoimmun. 2013;40:21-27.
7. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transversemyelitis. Ann Neurol. 2006;59(3):566-569.
8. Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008;70(23):2197-2200.
9. Iorio R, Damato V, Mirabella M, et al. Distinctive clinical and neuroimaging characteristics of longitudinally extensive transversemyelitis associated with aquaporin-4 autoantibodies. J Neurol. 2013;260(9):2396-2402.
10. Iorio R. Treatment-resistant depression and aquaporin-4 autoantibodies: is there a link? Biol Psychiatry. 2015;78(1):e1-e2. doi:10.1016/j.biopsych .2014.09.011
11. RastetterW, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med. 2004;55: 477-503.
12. Iorio R, Damato V, Alboini PE, Evoli A. Efficacy and safety of rituximab formyasthenia gravis: A systematic review and meta-analysis. J Neurol. 2015;262(5):1115-1119.
13. Jacob A,Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65(11):1443-1448.
14. Greenberg BM, Graves D, Remington G, et al. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler. 2012;18(7): 1022-1026.
15. Dai Y, Lu T,Wang Y, et al. Rapid exacerbation of neuromyelitis optica after rituximab treatment. J Clin Neurosci. 2016;26:168-170.
16. Perumal JS, Kister I, Howard J, Herbert J. Disease exacerbation after rituximab induction in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015;2(1):e61. doi:10.1212/NXI .0000000000000061
17. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64(7):1270-1272.
18. Beyer AM,Wandinger KP, Siebert E, Zschenderlein R, Klehmet J. Neuromyelitis optica in a patient with an early onset demyelinating episode: clinical and autoantibody findings. Clin Neurol Neurosurg. 2007;109(10):926-930.
19. Capobianco M, Malucchi S, di Sapio A, et al. Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). Neurol Sci. 2007;28(4):209-211.
20. Birnbaum J, Kerr D. Optic neuritis and recurrentmyelitis in a woman with systemic lupus erythematosus. Nat Clin Pract Rheumatol. 2008;4 (7):381-386.
21. Cassinotto C, Joux J, Chausson N, Smadja D, Cabre P. Failure of rituximab in relapsing neuromyelitis optica: case report with two-year prospective follow-up [in French]. Rev Neurol (Paris). 2008;164(4):394-397.
22. Jarius S, Aboul-Enein F,Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008;131(pt 11): 3072-3080.
23. Mangat P, Ravindran J, Cleland L, Limaye V. A case of longitudinally extensive transverse myelitis (LETM): neuromyelitis optica. Clin Rheumatol. 2008;27(suppl 2):S67-S69.
24. Mok CC, To CH, Mak A, Poon WL. Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J Rheumatol. 2008;35(1):172-174.
25. Nasir S, Kerr DA, Birnbaum J. Nineteen episodes of recurrentmyelitis in a woman with neuromyelitis optica and systemic lupus erythematosus. Arch Neurol. 2009;66(9):1160-1163.
26. Pellkofer HL, Suessmair C, Schulze A, Hohlfeld R, Kuempfel T. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab. Mult Scler. 2009;15(8): 1006-1008.
27. Garcia-Martin E, Pinilla I, Pueyo V, Gil L, Martinez-Morales J, Fernandez J. Bilateral internuclear ophthalmoplegia in a patient with Devic's neuromyelitis optica. Case Rep Neurol. 2010;2(3):139-144.
28. Sánchez-Carteyron A, Alarcia R, Ara JR, Martín J. Posterior reversible encephalopathy syndrome after rituximab infusion in neuromyelitis optica. Neurology. 2010;74(18):1471-1473.
29. Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, SheremataWA. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler. 2011;17(10):1225-1230.
30. Kim SH, KimW, Li XF, Jung IJ, Kim HJ. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011;68(11):1412-1420.
31. Mahmood NA, Silver K, Onel K, Ko M, Javed A. Efficacy and safety of rituximab in pediatric neuromyelitis optica. J Child Neurol. 2011;26(2): 244-247.
32. Nakashima I, Takahashi T, Cree BA, et al. Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J Clin Neurosci. 2011;18(7): 997-998.
33. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76(15):1310-1315.
34. Lindsey JW, Meulmester KM, Brod SA, Nelson F,Wolinsky JS. Variable results after rituximab in neuromyelitis optica. J Neurol Sci. 2012;317(1-2): 103-105.
35. Patel V, Griffith NC, Blackwood E, Dias M, Cordato DJ. Spectrum disorder of neuromyelitis optica in a patient presenting with intractable vomiting and hiccups, transversemyelitis and acute encephalopathy. J Clin Neurosci. 2012;19(11): 1576-1578.
36. Tosello B, Halbert C, Mancini J, Chabrol B, Boucraut J, Milh M. Neuromyelitis optica in children: two case reports [in French]. Arch Pediatr. 2012;19(8):827-831.
37. Ayzenberg I, Kleiter I, Schröder A, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol. 2013;70(3):394-397.
38. Bourre B, Lefaucheur R, Girault C. Treatment of NMO relapse in the elderly: rituximab when plasma exchange fails? Acta Neurol Belg. 2013;113(3):335-336.
39. Danés I, Agustí A, Vallano A, et al. Available evidence and outcome of off-label use of rituximab in clinical practice. Eur J Clin Pharmacol. 2013;69 (9):1689-1699.
40. Dembinski K, Gieron-Korthals M, Martinez CR, Rodriguez L. Neuromyelitis optica in child: diagnostic and therapeutic challenges. Case Rep Pediatr. 2013;2013:124929.
41. Feyissa AM, Singh P, Smith RG. Neuromyelitis optica in patients with coexisting human immunodeficiency virus infections. Mult Scler. 2013;19(10):1363-1366.
42. Gredler V, Mader S, Schanda K, et al. Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases. J Neurol Sci. 2013;328(1-2):77-82.
43. Ip VH, Lau AY, Au LW, et al. Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders. J Neurol Sci. 2013; 324(1-2):38-39.
44. Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70(9):1110-1117.
45. Ringelstein M, Harmel J, Distelmaier F, et al. Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum. Mult Scler. 2013;19(11):1544-1547.
46. Yang CS, Yang L, Li T, et al. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology. 2013;81(8): 710-713.
47. Alsharoqi I. Remarkable response of seropositive neuromyelitis optica to rituximab therapy: first report from kingdom of Bahrain. Mult Scler Relat Disord. 2014;3(6):761. doi:10.1016/j .msard.2014.09.206
48. Beres SJ, Graves J,Waubant E. Rituximab use in pediatric central demyelinating disease. Pediatr Neurol. 2014;51(1):114-118.
49. Berger JR, Neltner J, Smith C, Cambi F. Posterior reversible encephalopathy syndrome masquerading as progressive multifocal leukoencephalopathy in rituximab treated neuromyelitis optica. Mult Scler Relat Disord. 2014;3 (6):728-731.
50. Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83(2): 142-150.
51. Graves J, Vinayagasundaram U, Mowry EM, et al. Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica. Mult Scler Relat Disord. 2014;3(2):244-252.
52. He D, Yu Y, YanW,Dai Q, Xu Z, Chu L. Individualized rituximab treatment for relapsing neuromyelitis optica: A pediatric case report. Pediatr Neurol. 2014;51(2):255-258.
53. Longoni G, Banwell B, Filippi M, Yeh EA. Rituximab as a first-line preventive treatment in pediatric NMOSDs: preliminary results in 5 children. Neurol Neuroimmunol Neuroinflamm. 2014;1(4):e46. doi:10.1212/NXI.0000000000000046
54. Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71(3):324-330.
55. Musafir SK, Shalkhly K, Zayed A,Walli F. Neuromyelitis optica: case reports from Oman. Mult Scler Relat Disord. 2014;3(6):741-742. doi:10.1016/j .msard.2014.09.159
56. Plate A, Havla J, Kümpfel T. Late-onset neutropenia during long-term rituximab therapy in neuromyelitis optica. Mult Scler Relat Disord. 2014;3 (2):269-272.
57. Weinfurtner K, Graves J, Ness J, Krupp L, MilazzoM,Waubant E. Prolonged remission in neuromyelitis optica following cessation of rituximab treatment. J Child Neurol. 2015;30(10): 1366-1370.
58. Kim SH, Jeong IH, Hyun JW, et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol. 2015;72(9):989-995.
59. Radaelli M, Moiola L, Sangalli F, et al. Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Mult Scler. 2016;22(4):511-519.
60. Torres J, Pruitt A, Balcer L, Galetta S, Markowitz C, Dahodwala N. Analysis of the treatment of neuromyelitis optica. J Neurol Sci. 2015;351(1-2):31-35.
61. Zéphir H, Bernard-Valnet R, Lebrun C, et al. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. J Neurol. 2015; 262(10):2329-2335.
62. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013; 81(14):1197-1204.
63. Chamberlain N, Massad C, Oe T, Cantaert T, Herold KC, Meffre E. Rituximab does not reset defective early B cell tolerance checkpoints. J Clin Invest. 2016;126(1):282-287.
64. Bichuetti DB, Oliveira EM, Souza NA, Tintoré M, Gabbai AA. Patients with neuromyelitis optica have a more severe disease than patients with relapsing-remitting multiple sclerosis, including higher risk of dying of a demyelinating disease. Arq Neuropsiquiatr. 2013;71(5):275-279.